Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RARB | P10826 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12806617 | 0.90 | THRB (0.45) | THRBKMT2ATSHRL3MBTL1TAS1R3 | |
| SCHEMBL6360136 | 0.89 | THRB (0.44) | THRBKMT2ATSHRTAS1R3TAS1R1 | |
| SCHEMBL8961851 | 0.88 | THRB (0.44) | THRBKMT2ATP53ALDH1A1L3MBTL1 | |
| SCHEMBL10042216 | 0.88 | THRB (0.43) | THRBKMT2ATSHRALDH1A1L3MBTL1 | |
| SCHEMBL2398606 | 0.86 | KMT2A (0.50) | THRBKMT2APLA2G4BMAPK1TP53 | |
| SCHEMBL9915736 | 0.81 | THRB (0.39) | THRBKMT2AMAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL12950565 | 0.80 | L3MBTL1 (0.41) | THRBKMT2AL3MBTL1TAS1R3TAS1R1 | |
| SCHEMBL12618473 | 0.79 | THRB (0.36) | THRBKMT2AALDH1A1MAPT | |
| SCHEMBL12618295 | 0.79 | THRB (0.36) | THRBKMT2AALDH1A1RARBMAPT | |
| SCHEMBL9908931 | 0.79 | BCHE (0.42) | THRBKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6616990-B2 | Dopes for liquid crystals | BASF AKTIENGESELLSCHAFT (DE) | 2003-09-09 | — | — | US | disclosed |
| US-20010030312-A1 | Dopes for liquid crystals | BASF AKTIENGESELLSCHAFT (DE) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010030312-A1 | Dopes for liquid crystals | DRD1, PDE6A, DRD3 | THRB 3587/4885KMT2A 4310/4885PLA2G4B 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.